CE-158

CE-158 is an atypical dopamine reuptake inhibitor (DRI) derived from modafinil. It is often referred to as the enantiopure enantiomer (S,S)-CE-158. CE-158 is a highly selective DRI with significantly greater potency than modafinil.

CE-158 demonstrates pro-motivational effects in animals, reverses tetrabenazine-induced motivational deficits, increases dopamine levels in the nucleus accumbens, blocks amphetamine-induced dopamine release in vitro, and enhances learning in animals.

It shows no effect on locomotor activity except at high doses. CE-158 is of interest for potential treatment of motivational disorders, psychostimulant use disorder (PSUD), and Alzheimer’s disease. It was first described in 2020 and is closely related to CE-123, an earlier modafinil analogue.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/CE-158
https://pmc.ncbi.nlm.nih.gov/articles/PMC9033101/